Pharmaceutical Executive-01-15-2009

The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral.

Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good?

Long-standing Nycomed CEO Håkan Björklund tells Pharm Exec Europe how the company is looking to new products, and new territories, to combat the patent expiry of its biggest product.